Table 1.

All preclinical studies mentioned above that have considered gabexate mesylate.

Author, reference, year	Drug/s	Tumor target	Molecular mechanisms of action	Results
Yoon et al. [46] 2004	gabexate mesylate	several human colon cancer cell lines	(1) down-regulation of MMPs (2) inhibition of uPA-plasmin system	inhibition of angiogenesis, tumor cell growth, invasion, metastasis
Brandi et al. [47] 2012	(1) gabexate mesylate  (2) gabexate mesylate plus cetuximab	several human colorectal cancer cell lines (wt/mut KRAS, BRAF, PIK3CA)	not analyzed	(1) inhibition of tumor cell growth, angiogenesis, invasion, metastasis (2) antitumoral efficacy of the combination therapy was not superior than gabexate mesylate alone
Uchima et al. [48] 2003	gabexate mesylate	several human pancreatic cancer cell lines	down-regulation of uPA, TAT, PAT, MMPs, TGF-β1, VEGF	inhibition of angiogenesis, cell growth, invasion, metastasis

MMPs, Metalloproteinases; uPA, urokinase-type plasminogen activator; wt, wild-type; mut, mutated; TAT, Tumor-associated trypsinogen; PAT, Pancreatic acinar trypsinogen; TGF-β1, Tumor growth factor-beta1; VEGF, Vascular endothelial growth factor.